Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
The Faber Difference
Values & Community
Our Clients
Areas of Expertise
Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Getting ready for a global Phase 2 or 3 clinical trial
Our experienced contracts specialists work alongside attorneys steeped in the business side of life sciences
Establishing a pharmaceutical supply chain
Our team of professionals understands the industry-specific drivers of complex supply chains
The Faber Difference
Values & Community
Our Clients
Areas of Expertise
Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Getting ready for a global Phase 2 or 3 clinical trial
Our experienced contracts specialists work alongside attorneys steeped in the business side of life sciences
Establishing a pharmaceutical supply chain
Our team of professionals understands the industry-specific drivers of complex supply chains
News
Faber recently announced the addition of Melissa Paddock as the firm’s newest counsel. “Melissa is an accomplished attorney with a strong background in intellectual property-related transactions from her many years counseling clients in both law firm and in house counsel roles,” said Faber principal Sumy Daeufer. Paddock will advise Faber clients regarding licensing arrangements, clinical trials, sponsored research, technology evaluation and various other life sciences agreements.
Prior to joining the firm, Paddock practiced for six years in the strategic technology transactions and licensing group of a leading global law firm. “I represented biotechnology, pharmaceutical, medical device and other life science companies in drafting and negotiating a wide range of intellectual property, R&D and commercial transactions,” she explained. “Most recently, I served as in-house contracts counsel at a gene therapy company.”
Paddock says that she was impressed by the firm’s sophisticated life sciences and emerging technology practice, and by the deep bench of skilled attorneys and contracts specialists existing in a smaller law firm. “It’s a terrific group of skilled attorneys and contracts specialists, most with significant real-world experience at biotech and pharma companies, who provide high quality legal advice that is both thoughtful and practical. I was excited about joining such a talented team.”
The firm’s culture was also a very important factor for Paddock. “There is a true collaborative approach to sharing knowledge and working together to serve clients at Faber. I was also struck by the firm’s commitment to each person’s professional development. The firm acknowledges the different experience and knowledge that each new employee brings to the firm and crafts an individualized development plan to provide thoughtful training and growth opportunities.”
Daeufer is enthusiastic about Paddock and the unique contributions she will make to the firm. “She will be assisting clients with a wide array of life sciences research and development transactions, and our clients will benefit from her deep experience and pragmatic and business-savvy counsel.”
Paddock is also excited about joining the firm, and looks forward to providing meaningful counsel to Faber’s clients. “I hope that by leveraging both my experience at a big firm and at a small biotech, I can help address our clients’ needs in a thoughtful and pragmatic way and make a meaningful contribution to the team.”